SMI closes 0.11 percent higher at 15,053.86 points
Published on 11/11/2026 at 22:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSMI ends above 15,000 points
- The SMI closed on November 11, 2026, at 15,053.86 points, up 0.11 percent from Tuesday's close.
- Technology shares and renewed confidence in the artificial-intelligence sector supported the market, while Novartis and Alcon weighed on the index.
- The defensive SMI lagged stronger gains in several other European benchmarks.
The Swiss Market Index (SMI) finished Wednesday, November 11, 2026, at 15,053.86 points. That was an increase of 15.92 points, or 0.11 percent, from Tuesday's closing level of 15,037.94 points. The result kept Switzerland's blue-chip benchmark above the psychologically important 15,000-point threshold.
The closing level and session change were reported by finanzen.ch, which cited Swiss market data. The SMI is the price index for the 20 largest and most liquid equities in Switzerland, according to SIX. The index is calculated in real time from transactions in its constituents.
Technology shares support the market
Market sentiment benefited from renewed interest in technology stocks and greater confidence in the artificial-intelligence theme. Finanzen.ch reported that CoreWeave's results helped restore confidence in the sector, while concerns about persistent inflation and the possibility of further US interest-rate increases remained in the background. Oil prices also recovered somewhat after their recent decline.
Logitech led the SMI gainers, rising 4.0 percent. Galderma gained 3.4 percent, Sandoz advanced 2.2 percent and ABB climbed 2.5 percent. ABB also benefited from strong results from Siemens Energy, according to the report. Semiconductor-related shares VAT, Comet and AMS Osram also posted strong gains.
Heavyweights limit the advance
The index's performance was restrained by declines in major constituents. Novartis fell 1.3 percent, while Nestle declined 0.6 percent. Alcon was the weakest SMI constituent, losing 3.9 percent after its results, as analysts criticized the company's third-quarter revenue development. Roche shares were nearly unchanged.
The SMI's 0.11 percent advance was weaker than the gains in several other European markets. The broader Swiss SPI rose 0.24 percent, while the SMIM mid-cap index gained 0.67 percent. For investors, the session again highlighted the influence of individual large-cap healthcare companies on the market-capitalization-weighted benchmark.
More coverage of the SMI is available on the topic page.
